神経内分泌腫瘍（NET）の世界市場（2024年版）：治療別、投与経路別、適応症別、エンドユーザー別、地域別の分析、市場考察、予測（2020年～2030年）

世界の神経内分泌腫瘍（NET）の市場規模は、2020年～2023年にCAGRで8.98%の成長を示しました。市場規模は2023年に35億7,000万米ドルであり、2030年に69億4,000万米ドルに達すると予測されています。市場は、NETの罹患率と有病率の増加、医療費の増加、老年人口の増加、医療インフラの向上、啓発キャンペーンや患者支援活動の高まりにより、大幅な成長を示しています。

近年、世界中でNETの罹患率と有病率が顕著に増加しています。この動向には、発見率の向上につながる診断技術の向上、医療従事者の意識の高まり、高齢化など、複数の要因が寄与しています。より多くの症例が診断されるにつれ、NET患者に対する診断検査、治療オプション、支持療法サービスに対する需要は増加の一途をたどっています。

さらに、標的治療薬や新治療法の登場により、NETの治療は大きく変化しています。オクトレオチドやランレオチドなどのソマトスタチン類似体は、NETの特定のサブタイプにおいてホルモン症状を制御し、腫瘍の成長を抑制します。PRRTは、ソマトスタチン受容体を発現している腫瘍細胞に標的放射線を照射するもので、疾患が進行した患者に有望な治療オプションを提供します。さらに、進行中の免疫療法、併用療法、遺伝子ベースのアプローチに関する研究は、NETの治療法をさらに拡大する可能性を秘めており、市場成長を促進しています。

精密医療と分子診断の進歩により、個々の腫瘍の分子特性に合わせた個別化治療戦略が可能になります。バイオマーカー主導のアプローチでは、特定の腫瘍マーカー、ソマトスタチン受容体の発現パターン、遺伝子変化に基づいて、SSA療法がもっとも有効な患者を特定します。これにより、より的を絞った効果的な治療選択が可能となり、不必要な薬物への曝露を最小限に抑えながら治療結果を最適化することができます。

また、ナノテクノロジーの進歩により、NET治療の非経口投与に用いるマイクロスフェアやナノ粒子製剤の開発が可能になっています。これらの製剤は、生分解性ポリマーマトリクスや脂質ベースのナノ粒子内に薬剤をカプセル化し、放出制御と腫瘍組織への標的送達を可能にしています。ミクロスフェアやナノ粒子製剤は、薬物の安定性の向上、腫瘍への浸透性の強化、体内での循環時間の延長などの利点を提供します。薬物の薬物動態と生体内分布を最適化することにより、これらの製剤は標的外の影響を最小限に抑えながら治療結果を向上させます。

進行中の調査では、消化管NETにおける局所ドラッグデリバリーや画像誘導治療に向けた標的内視鏡デリバリーシステムが研究されています。薬剤溶出ステント、マイクロインジェクター、磁気ナビゲーションシステムなどの新しい内視鏡プラットフォームは、治療薬を腫瘍部位に直接正確に送達することを可能にします。これらの標的送達システムは、化学療法、免疫療法、ペプチド受容体放射性核種療法（PRRT）などの治療法の有効性と安全性を高め、全身被曝や標的外の影響を最小限に抑えることができます。リアルタイムイメージングとナビゲーション機能により、正確な位置特定と治療反応のモニタリングが可能になり、治療結果を最適化すると同時に、手技による合併症を最小限に抑えることができます。

当レポートでは、世界の神経内分泌腫瘍（NET）市場について調査し、市場規模と予測、地域とセグメントの分析、主要動向と機会などの情報を提供しています。

目次

第1章 市場背景

• 範囲と製品の見通し
• エグゼクティブサマリー
• 調査手法

第2章 戦略的推奨

• 専門治療センターの設立
• 意識向上キャンペーンの運営

第3章 世界の神経内分泌腫瘍（NET）市場：実績と予測

• 世界の神経内分泌腫瘍（NET）市場に対するマクロ経済要因の影響の分析
• パイプラインのシナリオ
• 疫学：世界のNETの有病率
• 疫学：世界のNETの罹患率
• 世界の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
• 神経内分泌腫瘍（NET）市場に対するCOVID-19の影響度
• 世界の神経内分泌腫瘍（NET）市場セグメンテーション：治療別
  • 世界の神経内分泌腫瘍（NET）市場：治療別、概要
  • 世界の神経内分泌腫瘍（NET）市場の魅力指数：治療別、概要
  • 世界の神経内分泌腫瘍（NET）の市場規模：ソマトスタチン類似体（SSA）（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：標的治療法（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：その他（金額）（2020年～2030年）
• 世界の神経内分泌腫瘍（NET）市場セグメンテーション：投与経路別
  • 世界の神経内分泌腫瘍（NET）市場：投与経路別、概要
  • 世界の神経内分泌腫瘍（NET）市場の魅力指数：投与経路別、概要
  • 世界の神経内分泌腫瘍（NET）の市場規模：経口（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：非経口（金額）（2020年～2030年）
• 世界の神経内分泌腫瘍（NET）市場セグメンテーション：適応症別
  • 世界の神経内分泌腫瘍（NET）市場：適応症別、概要
  • 世界の神経内分泌腫瘍（NET）市場の魅力指数：適応症別、概要
  • 世界の神経内分泌腫瘍（NET）の市場規模：肺内分泌腫瘍（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：膵臓内分泌腫瘍（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：消化管内分泌腫瘍（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：その他（金額）（2020年～2030年）
• 世界の神経内分泌腫瘍（NET）市場セグメンテーション：エンドユーザー別
  • 世界の神経内分泌腫瘍（NET）市場：エンドユーザー別、概要
  • 世界の神経内分泌腫瘍（NET）市場の魅力指数：エンドユーザー別、概要
  • 世界の神経内分泌腫瘍（NET）の市場規模：病院（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：専門クリニック（金額）（2020年～2030年）
  • 世界の神経内分泌腫瘍（NET）の市場規模：放射線センター（金額）（2020年～2030年）

第4章 世界の神経内分泌腫瘍（NET）市場、地域分析

• 調査の地域範囲
• 地域のスナップショット

第5章 南北アメリカの神経内分泌腫瘍（NET）市場：実績と予測

• 南北アメリカの神経内分泌腫瘍（NET）市場：概要
• 南北アメリカの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
• 南北アメリカの神経内分泌腫瘍（NET）市場：主な要因
• 南北アメリカの神経内分泌腫瘍（NET）市場：セグメント分析
• 南北アメリカの神経内分泌腫瘍（NET）市場セグメンテーション：治療別
• 南北アメリカの神経内分泌腫瘍（NET）市場セグメンテーション：投与経路別
• 南北アメリカの神経内分泌腫瘍（NET）市場セグメンテーション：適応症別
• 南北アメリカの神経内分泌腫瘍（NET）市場セグメンテーション：エンドユーザー別
• 南北アメリカの神経内分泌腫瘍（NET）市場セグメンテーション：国別
  • 欧州の神経内分泌腫瘍（NET）市場：国別、概要
  • 米国の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • カナダの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • その他の南北アメリカの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）

第6章 欧州の神経内分泌腫瘍（NET）市場：実績と予測

• 欧州の神経内分泌腫瘍（NET）市場：概要
• 欧州の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
• 欧州の神経内分泌腫瘍（NET）市場：主な要因
• 欧州の神経内分泌腫瘍（NET）市場：セグメント分析
• 欧州の神経内分泌腫瘍（NET）市場セグメンテーション：治療別
• 欧州の神経内分泌腫瘍（NET）市場セグメンテーション：投与経路別
• 欧州の神経内分泌腫瘍（NET）市場セグメンテーション：適応症別
• 欧州の神経内分泌腫瘍（NET）市場セグメンテーション：エンドユーザー別
• 欧州の神経内分泌腫瘍（NET）市場セグメンテーション：国別
  • 欧州の神経内分泌腫瘍（NET）市場：国別、概要
  • 英国の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • ドイツの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • フランスの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • スペインの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • その他の欧州の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）

第7章 アジア太平洋の神経内分泌腫瘍（NET）市場：実績と予測

• アジア太平洋の神経内分泌腫瘍（NET）市場：概要
• アジア太平洋の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
• アジア太平洋の神経内分泌腫瘍（NET）市場：主な要因
• アジア太平洋の神経内分泌腫瘍（NET）市場：セグメント分析
• アジア太平洋の神経内分泌腫瘍（NET）市場セグメンテーション：治療別
• アジア太平洋の神経内分泌腫瘍（NET）市場セグメンテーション：投与経路別
• アジア太平洋の神経内分泌腫瘍（NET）市場セグメンテーション：適応症別
• アジア太平洋の神経内分泌腫瘍（NET）市場セグメンテーション：エンドユーザー別
• アジア太平洋の神経内分泌腫瘍（NET）市場セグメンテーション：国別
  • アジア太平洋の神経内分泌腫瘍（NET）市場：国別、概要
  • 中国の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • 日本の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • インドの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • 韓国の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
  • その他のアジア太平洋の神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）

第8章 中東・アフリカの神経内分泌腫瘍（NET）市場：実績と予測

• 中東・アフリカの神経内分泌腫瘍（NET）市場：概要
• 中東・アフリカの神経内分泌腫瘍（NET）市場：市場規模とCAGR（2020年～2030年）
• 中東・アフリカの神経内分泌腫瘍（NET）市場：主な要因
• 中東・アフリカの神経内分泌腫瘍（NET）市場：セグメント分析
• 中東・アフリカの神経内分泌腫瘍（NET）市場セグメンテーション：治療別
• 中東・アフリカの神経内分泌腫瘍（NET）市場セグメンテーション：投与経路別
• 中東・アフリカの神経内分泌腫瘍（NET）市場セグメンテーション：適応症別
• 中東・アフリカの神経内分泌腫瘍（NET）市場セグメンテーション：エンドユーザー別

第9章 市場力学

• 世界の神経内分泌腫瘍（NET）市場に対する市場力学の影響の評価
• 促進要因
• 抑制要因
• 動向

第10章 産業エコシステム分析

• ポーター分析

第11章 競合ポジショニング

• 企業の製品ポジショニング
• 主要企業の市場シェア
• 企業プロファイル
  • Novartis
  • Pfizer
  • Amgen, Inc.
  • GlaxoSmithKline
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Company
  • Ipsen
  • Lantheus Holdings
  • Boehringer Ingelheim

第12章 当社について、免責事項

List of Figures

• Figure 1: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2020-2023 (USD Million)
• Figure 2: Global Neuroendocrine Tumors (NETs) Market Size, By Value, 2024-2030 (USD Million)
• Figure 3: Global Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
• Figure 4: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Therapy (2025-2030)
• Figure 5: Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
• Figure 6: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Somatostatin Analogs (SSAs), 2020H-2030F (USD Million)
• Figure 7: Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 8: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Targeted Therapy, 2020H-2030F (USD Million)
• Figure 9: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 10: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
• Figure 11: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Route of Administration (2025-2030)
• Figure 12: Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 13: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Oral, 2020H-2030F (USD Million)
• Figure 14: Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 15: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Parenteral, 2020H-2030F (USD Million)
• Figure 16: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By Indication (2025-2030)
• Figure 17: Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 18: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Lung Endocrine Tumor, 2020H-2030F (USD Million)
• Figure 19: Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 20: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Pancreatic Endocrine Tumor, 2020H-2030F (USD Million)
• Figure 21: Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 22: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Gastrointestinal Endocrine Tumor, 2020H-2030F (USD Million)
• Figure 23: Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 24: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Others, 2020H-2030F (USD Million)
• Figure 25: Market Attractiveness Analysis of Global Neuroendocrine Tumors (NETs) Market, By End User (2025-2030)
• Figure 26: Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 27: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Hospitals, 2020H-2030F (USD Million)
• Figure 28: Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 29: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Specialty Clinics, 2020H-2030F (USD Million)
• Figure 30: Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 31: Global Neuroendocrine Tumors (NETs) Market Absolute Opportunity, By Radiation Centers, 2020H-2030F (USD Million)
• Figure 32: Americas Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
• Figure 33: Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
• Figure 34: Americas Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
• Figure 35: Americas Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 36: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 37: Americas Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 38: Americas Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 39: Americas Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 40: Americas Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 41: Americas Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 42: Americas Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 43: Americas Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 44: Americas Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 45: Americas Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 46: United States Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 47: United States Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 48: United States Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 49: United States Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 50: United States Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 51: United States Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 52: Canada Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 53: Canada Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 54: Canada Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 55: Canada Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 56: Canada Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 57: Canada Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 58: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 59: Rest of Americas Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 60: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 61: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 62: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 63: Rest of Americas Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 64: Europe Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
• Figure 65: Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
• Figure 66: Europe Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
• Figure 67: Europe Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 68: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 69: Europe Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 70: Europe Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 71: Europe Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 72: Europe Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 73: Europe Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 74: Europe Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 75: Europe Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 76: Europe Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 77: Europe Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 78: United Kingdom Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 79: United Kingdom Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 80: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 81: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 82: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 83: United Kingdom Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 84: Germany Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 85: Germany Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 86: Germany Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 87: Germany Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 88: Germany Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 89: Germany Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 90: France Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 91: France Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 92: France Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 93: France Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 94: France Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 95: France Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 96: Spain Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 97: Spain Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 98: Spain Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 99: Spain Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 100: Spain Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 101: Spain Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 102: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 103: Rest of Europe Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 104: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 105: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 106: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 107: Rest of Europe Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 108: Asia-Pacific Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
• Figure 109: Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
• Figure 110: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
• Figure 111: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 112: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 113: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 114: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 115: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 116: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 117: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 118: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 119: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 120: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 121: Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 122: China Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 123: China Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 124: China Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 125: China Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 126: China Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 127: China Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 128: Japan Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 129: Japan Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 130: Japan Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 131: Japan Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 132: Japan Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 133: Japan Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 134: India Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 135: India Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 136: India Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 137: India Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 138: India Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 139: India Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 140: South Korea Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 141: South Korea Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 142: South Korea Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 143: South Korea Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 144: South Korea Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 145: South Korea Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 146: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 147: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Value, By Route of Administration, 2023 (USD Million)
• Figure 148: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Therapy, By Value, 2023 (%)
• Figure 149: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Route of Administration, By Value, 2023 (%)
• Figure 150: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By Indication, By Value, 2023 (%)
• Figure 151: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market Share, By End User, By Value, 2023 (%)
• Figure 152: Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Value, 2020H-2030F (USD Million)
• Figure 153: Middle East and Africa Neuroendocrine Tumors (NETs) Market Share, By Indication, 2023 (%)
• Figure 154: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
• Figure 155: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 156: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 157: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 158: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 159: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 160: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 161: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 162: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 163: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 164: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 165: Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• Figure 166: Global Impact of Drivers and Restraints
• Figure 167: Market Share of Prominent Companies of Neuroendocrine Tumors (NETs), 2023 (%)
• Figure 168: Novartis Revenues, 2021-2023 (USD Billion)
• Figure 169: Novartis Revenue , By Business Segments, 2023 (%)
• Figure 170: Novartis Revenue , By Geographical Segments, 2023 (%)
• Figure 171: Pfizer Revenues, 2021-2023 (USD Billion)
• Figure 172: Pfizer Revenues, By Business Segments, 2023 (%)
• Figure 173: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
• Figure 174: Amgen, Inc. Revenues, 2021-2023 (USD Million)
• Figure 175: Amgen, Inc. Revenues, By Geographic Segments, 2023 (%)
• Figure 176: Amgen, Inc. Revenue , By Products, 2023 (%)
• Figure 177: GSK Revenue, 2021-2023 (USD Billion)
• Figure 178: GSK Revenue , By Business Segments, 2023 (%)
• Figure 179: GSK Revenue, By Geographical Segment, 2023 (%)
• Figure 180: Roche Revenues, 2021-2023 (USD Billion)
• Figure 181: Roche Revenue , By Business Segment, 2023 (%)
• Figure 182: Bristol-Myers Squibb Revenues, 2021-2023 (USD Billion)
• Figure 183: Bristol-Myers Squibb Revenues, By Geographic Segments, 2023 (%)
• Figure 184: Eli Lilly and Company Revenues, 2021-2023 (USD Billion)
• Figure 185: Eli Lilly and Company Revenues, By Geographic Segments, 2023 (%)
• Figure 186: Eli Lilly and Company Revenue , By Business Segments, 2023 (%)
• Figure 187: Ipsen Revenues, 2021-2023 (USD Million)
• Figure 188: Ipsen Revenue, By Business Segments, 2023 (%)
• Figure 189: Ipsen Revenue, By Geographical Segments, 2023 (%)
• Figure 190: Lantheus Revenues, 2021-2023 (USD Million)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Neuroendocrine Tumor (NETs) Therapies in Pipeline

Table A3: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A4: United States Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A5: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A6: United States Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A7: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A8: United States Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A9: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A10: United States Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A11: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A12: Canada Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A13: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A14: Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A15: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A16: Canada Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A17: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A18: Canada Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A19: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A20: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A21: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A22: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A23: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A24: Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A25: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A26: Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A27: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A28: United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A29: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A30: United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A31: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A32: United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A33: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A34: United Kingdom Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A35: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A36: Germany Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A37: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A38: Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A39: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A40: Germany Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A41: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A42: Germany Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A43: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A44: France Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A45: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A46: France Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A47: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A48: France Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A49: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A50: France Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A51: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A52: Spain Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A53: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A54: Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A55: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A56: Spain Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A57: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A58: Spain Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A59: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A60: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A61: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A62: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A63: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A64: Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A65: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A66: Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A67: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A68: China Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A69: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A70: China Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A71: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A72: China Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A73: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A74: China Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A75: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A76: Japan Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A77: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A78: Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A79: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A80: Japan Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A81: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A82: Japan Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A83: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A84: India Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A85: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A86: India Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A87: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A88: India Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A89: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A90: India Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A91: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A92: South Korea Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A93: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A94: South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A95: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A96: South Korea Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A97: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A98: South Korea Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A99: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2020-2023 (USD Million)

Table A100: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Therapy, By Value, 2024-2030 (USD Million)

Table A101: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2020-2023 (USD Million)

Table A102: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration, By Value, 2024-2030 (USD Million)

Table A103: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2020-2023 (USD Million)

Table A104: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By Indication, By Value, 2024-2030 (USD Million)

Table A105: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2020-2023 (USD Million)

Table A106: Rest of Asia-Pacific Neuroendocrine Tumors (NETs) Market, By End User, By Value, 2024-2030 (USD Million)

Table A107: Novartis Key Company Financials, 2021-2023

Table A108: Pfizer Key Financials, 2021-2023

Table A109: Amgen, Inc. Key Financials, 2021-2023

Table A110: GSK Key Company Financials, 2021-2023

Table A111: Roche Key Financials, 2021-2023

Table A112: Bristol-Myers Squibb Key Financials, 2021-2023

Table A113: Eli Lilly and Company Key Financials, 2021-2023

Table A114: Ipsen Key Company Financials, 2021-2023

Table A115: Lantheus Key Company Financials, 2021-2023

Executive Summary

Azoth Analytics has released a research report titled "Global Neuroendocrine Tumors (NETs) Market (2024 Edition)" which provides a complete analysis of the Global Neuroendocrine Tumors (NETs) industry in terms of market segmentation by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), by Route of Administration (Oral, Parenteral), by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others), by End User (Hospitals, Specialty Clinics, Radiation Centers) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea). The Global Neuroendocrine Tumors (NETs) market showcased growth at a CAGR of 8.98% during 2020-2023. The market was valued at USD 3.57 Billion in 2023 which is expected to reach USD 6.94 Billion in 2030. The market for Neuroendocrine Tumors (NETs) has seen significant growth due to the increasing incidence and prevalence of NETs, rising healthcare expenditure, a growing geriatric population, improvements in healthcare infrastructure, and heightened awareness campaigns and patient advocacy efforts.

Over recent years, there has been a notable rise in the incidence and prevalence of NETs globally. Several factors contribute to this trend, including improved diagnostic techniques leading to better detection rates, heightened awareness among healthcare professionals, and an aging population. As more cases are diagnosed, the demand for diagnostic tests, treatment options, and supportive care services for NET patients continues to grow.

Furthermore, the emergence of targeted therapies and novel treatment modalities has transformed the management of NETs. Somatostatin analogs, such as octreotide and lanreotide, control hormonal symptoms and inhibit tumor growth in certain subtypes of NETs. PRRT delivers targeted radiation to tumor cells expressing somatostatin receptors, offering a promising therapeutic option for patients with advanced disease. Furthermore, ongoing research into immunotherapies, combination therapies, and gene-based approaches holds potential for further expanding the treatment armamentarium for NETs, driving market growth.

Advancement in precision medicine and molecular diagnostics enable personalized treatment strategies tailored to the molecular characteristics of individual tumors. Biomarker-driven approaches identify patients who are most likely to benefit from SSA therapy based on specific tumor markers, somatostatin receptor expression patterns, and genetic alterations. This allows for more targeted and effective treatment selection, optimizing therapeutic outcomes while minimizing unnecessary exposure to medications.

Also, advancement in nanotechnology enable the development of microsphere and nanoparticle formulations for parenteral administration of NETs therapies. These formulations encapsulate the drug within biodegradable polymer matrices or lipid-based nanoparticles, allowing for controlled release and targeted delivery to tumor tissues. Microsphere and nanoparticle formulations offer advantages such as improved drug stability, enhanced tumor penetration, and prolonged circulation time in the body. By optimizing drug pharmacokinetics and biodistribution, these formulations enhance treatment outcomes while minimizing off-target effects.

Ongoing research explores targeted endoscopic delivery systems for localized drug delivery and image-guided therapy in gastrointestinal NETs. Novel endoscopic platforms, such as drug-eluting stents, micro-injectors, and magnetic navigation systems, enable precise delivery of therapeutic agents directly to the tumor site. These targeted delivery systems enhance the efficacy and safety of treatment modalities, such as chemotherapy, immunotherapy, and peptide receptor radionuclide therapy (PRRT), by minimizing systemic exposure and off-target effects. Real-time imaging and navigation capabilities allow for precise localization and monitoring of therapeutic response, optimizing treatment outcomes while minimizing procedural complications.

Scope of the Report:

• The report analyses the Neuroendocrine Tumors (NETs) Market by Value (USD Million).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Pipeline Scenario.
• The report analyses the Neuroendocrine Tumors (NETs) Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, India, Japan, South Korea).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Epidemiology.
• The report presents the analysis of Neuroendocrine Tumors (NETs) Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
• The report analyses the Neuroendocrine Tumors (NETs) Market by Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Route of Administration (Oral, Parenteral).
• The report analyses the Neuroendocrine Tumors (NETs) Market by Indication (Lung Endocrine Tumor, Pancreatic Endocrine Tumor, Gastrointestinal Endocrine Tumor, Others).
• The report analyses the Neuroendocrine Tumors (NETs) Market by End User (Hospitals, Specialty Clinics, Radiation Centers).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by source, by application, by indication, & by end user.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Pfizer, Amgen, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Ipsen, Lantheus Holdings, and Boehringer Ingelheim.

Table of Contents

1. Market Background

• 1.1 Scope and Product Outlook
• 1.2 Executive Summary
• 1.3 Research Methodology

2. Strategic Recommendations

• 2.1 Establishment of specialist therapeutic centers
• 2.2 Organize campaigns to raise awareness

3. Global Neuroendocrine Tumors (NETs) Market: Historic and Forecast

• 3.1 Impact Analysis of Macro Economic Factors on Global Neuroendocrine Tumors (NETs) Market
• 3.2 Pipeline Scenario
• 3.3 Epidemiology: Global NETs Prevalence
• 3.4 Epidemiology: Global NETs Incidence
• 3.5 Global Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 3.6 Degree of Impact of Covid-19 on Neuroendocrine Tumors (NETs) Market
• 3.7 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
  • 3.7.1 Global Neuroendocrine Tumors (NETs) Market, By Therapy Overview
  • 3.7.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Therapy Overview
  • 3.7.3 Global Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • 3.7.4 Global Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.7.5 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 3.8 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
  • 3.8.1 Global Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
  • 3.8.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Route of Administration Overview
  • 3.8.3 Global Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.8.4 Global Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 3.9 Global Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
  • 3.9.1 Global Neuroendocrine Tumors (NETs) Market, By Indication Overview
  • 3.9.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By Indication Overview
  • 3.9.3 Global Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9.4 Global Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9.5 Global Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9.6 Global Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 3.10 Global Neuroendocrine Tumors (NETs) Market Segmentation: By End User
  • 3.10.1 Global Neuroendocrine Tumors (NETs) Market, By End User Overview
  • 3.10.2 Global Neuroendocrine Tumors (NETs) Market Attractiveness Index, By End User Overview
  • 3.10.3 Global Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10.4 Global Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10.5 Global Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

4. Global Neuroendocrine Tumors (NETs) Market, Region Analysis

• 4.1 Regional Coverage of the Study
• 4.2 Regional Snapshot

5. Americas Neuroendocrine Tumors (NETs) Market: Historic and Forecast

• 5.1 Americas Neuroendocrine Tumors (NETs) Market: Snapshot
• 5.2 Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 5.3 Americas Neuroendocrine Tumors (NETs) Market: Key Factors
• 5.4 Americas Neuroendocrine Tumors (NETs) Market: Segment Analysis
• 5.5 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
  • 5.5.1 Americas Neuroendocrine Tumors (NETs) Market, By Therapy Overview
  • 5.5.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.5.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 5.6 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
  • 5.6.1 Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
  • 5.6.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.6.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 5.7 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
  • 5.7.1 Americas Neuroendocrine Tumors (NETs) Market, By Indication Overview
  • 5.7.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7.5 Americas Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 5.8 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By End User
  • 5.8.1 Americas Neuroendocrine Tumors (NETs) Market, By End User Overview
  • 5.8.2 Americas Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8.3 Americas Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8.4 Americas Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• 5.9 Americas Neuroendocrine Tumors (NETs) Market Segmentation: By Country
  • 5.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
  • 5.9.2 United States Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.9.2.1 United States Neuroendocrine Tumors (NETs) Market, By Therapy
    • 5.9.2.2 United States Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 5.9.2.3 United States Neuroendocrine Tumors (NETs) Market, By Indication
    • 5.9.2.4 United States Neuroendocrine Tumors (NETs) Market, By End User
  • 5.9.3 Canada Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.9.3.1 Canada Neuroendocrine Tumors (NETs) Market, By Therapy
    • 5.9.3.2 Canada Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 5.9.3.3 Canada Neuroendocrine Tumors (NETs) Market, By Indication
    • 5.9.3.4 Canada Neuroendocrine Tumors (NETs) Market, By End User
  • 5.9.4 Rest of Americas Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 5.9.4.1 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Therapy
    • 5.9.4.2 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 5.9.4.3 Rest of Americas Neuroendocrine Tumors (NETs) Market, By Indication
    • 5.9.4.4 Rest of Americas Neuroendocrine Tumors (NETs) Market, By End User

6. Europe Neuroendocrine Tumors (NETs) Market: Historic and Forecast

• 6.1 Europe Neuroendocrine Tumors (NETs) Market: Snapshot
• 6.2 Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 6.3 Europe Neuroendocrine Tumors (NETs) Market: Key Factors
• 6.4 Europe Neuroendocrine Tumors (NETs) Market: Segment Analysis
• 6.5 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
  • 6.5.1 Europe Neuroendocrine Tumors (NETs) Market, By Therapy Overview
  • 6.5.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.5.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 6.6 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
  • 6.6.1 Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
  • 6.6.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.6.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 6.7 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
  • 6.7.1 Europe Neuroendocrine Tumors (NETs) Market, By Indication Overview
  • 6.7.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7.5 Europe Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 6.8 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By End User
  • 6.8.1 Europe Neuroendocrine Tumors (NETs) Market, By End User Overview
  • 6.8.2 Europe Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8.3 Europe Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8.4 Europe Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• 6.9 Europe Neuroendocrine Tumors (NETs) Market Segmentation: By Country
  • 6.9.1 Europe Neuroendocrine Tumors (NETs) Market, By Country Overview
  • 6.9.2 United Kingdom Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.9.2.1 United Kingdom Neuroendocrine Tumors (NETs) Market, By Therapy
    • 6.9.2.2 United Kingdom Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 6.9.2.3 United Kingdom Neuroendocrine Tumors (NETs) Market, By Indication
    • 6.9.2.4 United Kingdom Neuroendocrine Tumors (NETs) Market, By End User
  • 6.9.3 Germany Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.9.3.1 Germany Neuroendocrine Tumors (NETs) Market, By Therapy
    • 6.9.3.2 Germany Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 6.9.3.3 Germany Neuroendocrine Tumors (NETs) Market, By Indication
    • 6.9.3.4 Germany Neuroendocrine Tumors (NETs) Market, By End User
  • 6.9.4 France Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.9.4.1 France Neuroendocrine Tumors (NETs) Market, By Therapy
    • 6.9.4.2 France Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 6.9.4.3 France Neuroendocrine Tumors (NETs) Market, By Indication
    • 6.9.4.4 France Neuroendocrine Tumors (NETs) Market, By End User
  • 6.9.5 Spain Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.9.5.1 Spain Neuroendocrine Tumors (NETs) Market, By Therapy
    • 6.9.5.2 Spain Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 6.9.5.3 Spain Neuroendocrine Tumors (NETs) Market, By Indication
    • 6.9.5.4 Spain Neuroendocrine Tumors (NETs) Market, By End User
  • 6.9.6 Rest of Europe Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 6.9.6.1 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Therapy
    • 6.9.6.2 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 6.9.6.3 Rest of Europe Neuroendocrine Tumors (NETs) Market, By Indication
    • 6.9.6.4 Rest of Europe Neuroendocrine Tumors (NETs) Market, By End User

7. Asia Pacific Neuroendocrine Tumors (NETs) Market: Historic and Forecast

• 7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market: Snapshot
• 7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market: Key Factors
• 7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market: Segment Analysis
• 7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
  • 7.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy Overview
  • 7.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.5.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 7.6 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
  • 7.6.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
  • 7.6.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.6.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 7.7 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
  • 7.7.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication Overview
  • 7.7.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7.5 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 7.8 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By End User
  • 7.8.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User Overview
  • 7.8.2 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8.3 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8.4 Asia Pacific Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)
• 7.9 Asia Pacific Neuroendocrine Tumors (NETs) Market Segmentation: By Country
  • 7.9.1 Asia Pacific Neuroendocrine Tumors (NETs) Market, By Country Overview
  • 7.9.2 China Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.9.2.1 China Neuroendocrine Tumors (NETs) Market, By Therapy
    • 7.9.2.2 China Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 7.9.2.3 China Neuroendocrine Tumors (NETs) Market, By Indication
    • 7.9.2.4 China Neuroendocrine Tumors (NETs) Market, By End User
  • 7.9.3 Japan Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.9.3.1 Japan Neuroendocrine Tumors (NETs) Market, By Therapy
    • 7.9.3.2 Japan Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 7.9.3.3 Japan Neuroendocrine Tumors (NETs) Market, By Indication
    • 7.9.3.4 Japan Neuroendocrine Tumors (NETs) Market, By End User
  • 7.9.4 India Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.9.4.1 India Neuroendocrine Tumors (NETs) Market, By Therapy
    • 7.9.4.2 India Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 7.9.4.3 India Neuroendocrine Tumors (NETs) Market, By Indication
    • 7.9.4.4 India Neuroendocrine Tumors (NETs) Market, By End User
  • 7.9.5 South Korea Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.9.5.1 South Korea Neuroendocrine Tumors (NETs) Market, By Therapy
    • 7.9.5.2 South Korea Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 7.9.5.3 South Korea Neuroendocrine Tumors (NETs) Market, By Indication
    • 7.9.5.4 South Korea Neuroendocrine Tumors (NETs) Market, By End User
  • 7.9.6 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
    • 7.9.6.1 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Therapy
    • 7.9.6.2 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Route of Administration
    • 7.9.6.3 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By Indication
    • 7.9.6.4 Rest of Asia Pacific Neuroendocrine Tumors (NETs) Market, By End User

8. Middle East and Africa Neuroendocrine Tumors (NETs) Market: Historic and Forecast

• 8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Snapshot
• 8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
• 8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Key Factors
• 8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market: Segment Analysis
• 8.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Therapy
  • 8.5.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Therapy Overview
  • 8.5.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Somatostatin Analogs (SSAs), By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Targeted Therapy, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.5.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 8.6 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Route of Administration
  • 8.6.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Route of Administration Overview
  • 8.6.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.6.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
• 8.7 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By Indication
  • 8.7.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Indication Overview
  • 8.7.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Lung Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Pancreatic Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Gastrointestinal Endocrine Tumor, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7.5 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By Others, By Value, 2020H-2030F (USD Million & CAGR)
• 8.8 Middle East and Africa Neuroendocrine Tumors (NETs) Market Segmentation: By End User
  • 8.8.1 Middle East and Africa Neuroendocrine Tumors (NETs) Market, By End User Overview
  • 8.8.2 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.8.3 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.8.4 Middle East and Africa Neuroendocrine Tumors (NETs) Market Size, By Radiation Centers, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

• 9.1 Impact assessment of Market Dynamics on Global Neuroendocrine Tumors (NETs) Market
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Trends

10. Industry Ecosystem Analysis

• 10.1 Porter Analysis

11. Competitive Positioning

• 11.1 Companies' Product Positioning
• 11.2 Market Share of Leading Companies
• 11.3 Company Profiling
  • 11.3.1 Novartis
  • 11.3.2 Pfizer
  • 11.3.3 Amgen, Inc.
  • 11.3.4 GlaxoSmithKline
  • 11.3.5 F. Hoffmann-La Roche AG
  • 11.3.6 Bristol-Myers Squibb Co.
  • 11.3.7 Eli Lilly and Company
  • 11.3.8 Ipsen
  • 11.3.9 Lantheus Holdings
  • 11.3.10 Boehringer Ingelheim

12. About Us and Disclaimer